# Daphne S. Bakker

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/daphne-s-bakker/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,538 |
| Field | Dermatology and Skin Diseases |
| h-index | 22 |
| i10-index | 32 |
| Last Known Institution | Utrecht University |
| OpenAlex ID | https://openalex.org/A5025499079 |
| ORCID iD | 0000-0002-0193-5794 |
| Works | 58 |

## Researcher papers

- [Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis](https://scholariq.org/papers/goblet-cell-scarcity-and-conjunctival-inflammation-during-treatment-with/)
- [Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry](https://scholariq.org/papers/dupilumab-is-very-effective-in-a-large-cohort-of-difficult-to-treat-adult-atopic/)
- [Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers](https://scholariq.org/papers/confirmation-of-multiple-endotypes-in-atopic-dermatitis-based-on-serum/)
- [Biomarkers in atopic dermatitis](https://scholariq.org/papers/biomarkers-in-atopic-dermatitis/)
- [Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry](https://scholariq.org/papers/dupilumab-shows-long-term-effectiveness-in-a-large-cohort-of-treatment/)
- [Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/early-and-long-term-effects-of-dupilumab-treatment-on-circulating-t-cell/)
- [Dupilumab facial redness: Positive effect of itraconazole](https://scholariq.org/papers/dupilumab-facial-redness-positive-effect-of-itraconazole/)
- [Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis](https://scholariq.org/papers/patient-centered-dupilumab-dosing-regimen-leads-to-successful-dose-reduction-in/)
- [Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis](https://scholariq.org/papers/long-term-follow-up-and-treatment-outcomes-of-conjunctivitis-during-dupilumab/)
- [Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis](https://scholariq.org/papers/dupilumab-associated-lymphoid-reactions-in-patients-with-atopic-dermatitis/)
- [Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry](https://scholariq.org/papers/rapid-and-sustained-effect-of-dupilumab-on-work-productivity-in-patients-with/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

## Researcher university

- [Utrecht University](https://scholariq.org/institutions/utrecht-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.